CryoPort, Inc. (NASDAQ:CYRX) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.
CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, August 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. CryoPort had a negative net margin of 102.89% and a negative return on equity of 67.75%. The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $2.84 million. On average, analysts expect CryoPort to post $-0.31 EPS for the current fiscal year and $-0.23 EPS for the next fiscal year.
Shares of CryoPort, Inc. (CYRX) opened at 7.85 on Wednesday. CryoPort, Inc. has a 12-month low of $1.96 and a 12-month high of $10.40. The stock’s 50 day moving average is $8.73 and its 200-day moving average is $5.96. The stock’s market cap is $193.69 million.
A number of research analysts have recently weighed in on CYRX shares. Needham & Company LLC raised their price target on CryoPort from $8.50 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, August 30th. Janney Montgomery Scott started coverage on CryoPort in a research report on Wednesday, July 12th. They issued a “buy” rating and a $8.00 price target for the company. Finally, Cowen and Company restated an “outperform” rating and issued a $11.00 price target (up previously from $7.50) on shares of CryoPort in a research report on Tuesday, September 12th.
A hedge fund recently raised its stake in CryoPort stock. Northern Trust Corp grew its position in CryoPort, Inc. (NASDAQ:CYRX) by 105.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,179 shares of the company’s stock after buying an additional 11,358 shares during the quarter. Northern Trust Corp owned 0.09% of CryoPort worth $109,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.10% of the company’s stock.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.